Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib
Authors:
Open Access
- 1 November 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (45) , e13113
Abstract
Rationale: Pancreatic acinar cell carcinoma (PACC) is a relatively rare malignancy of the exocrine pancreas. BRCA2, a cancer susceptibility gene, has been widely studied in breast and ovarian carcinomas as mutation carriers for this gene are at a high risk for cancer development. Olaparib, an oral poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been approved for the treatment of ovarian cancer with any BRCA 1/2 mutations. Herein, we report the first case of a germline BRCA2-mutated unresectable advanced PACC patient who responded well to olaparib treatment. Patient concerns: A 59-year-old male with a family history of cancer presented with a persistent epigastric dull pain for 3 months. Diagnosis: The patient was diagnosed with advanced PACC based on computed tomography (CT) scan, laparotomy, and pathology. Interventions: Exploratory laparotomy, intratumoral brachytherapy by radioiodine-125 seeds, modified FOLFIRINOX chemotherapy, and targeted therapy with olaparib were administered. Outcomes: The patient responded well to olaparib until the occurrence of severe adverse drug reactions, he died as a result of multiple organ failure with an overall survival period of 12 months. Lessons: As a PARP inhibitor, olaparib has remarkable curative effect not only on breast and ovarian cancers, but also on other malignancies with BRCA mutations. Patients with advanced cancer could benefit from active targeted therapy with improvement in overall survival and quality of life.Keywords
This publication has 29 references indexed in Scilit:
- Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumorsWorld Journal of Gastroenterology, 2017
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of actionScience Translational Medicine, 2016
- Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair GenesCancer Discovery, 2014
- Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 casesVirchows Archiv, 2014
- Whole‐exome sequencing of pancreatic neoplasms with acinar differentiationThe Journal of Pathology, 2013
- Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term SurvivorsClinical Cancer Research, 2012
- The role of BRCA1 and BRCA2 in prostate cancerAsian Journal of Andrology, 2012
- Acinar Cell Carcinoma of the PancreasJournal of Computer Assisted Tomography, 2004
- Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related TumorsJournal of Clinical Oncology, 2002
- Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinomaThe Journal of Pathology, 1985